94 related articles for article (PubMed ID: 18419622)
61. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
62. CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.
Mi JQ; Xu J; Zhou J; Zhao W; Chen Z; Melenhorst JJ; Chen S
Front Med; 2021 Dec; 15(6):783-804. PubMed ID: 34921673
[TBL] [Abstract][Full Text] [Related]
63. Treatment resistance in diffuse large B-cell lymphoma.
He MY; Kridel R
Leukemia; 2021 Aug; 35(8):2151-2165. PubMed ID: 34017074
[TBL] [Abstract][Full Text] [Related]
64. Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
Gao Y; Sun B; Hu J; Ren H; Zhou H; Chen L; Liu R; Zhang W
Pharmacogenomics J; 2020 Oct; 20(5):705-716. PubMed ID: 32042095
[TBL] [Abstract][Full Text] [Related]
65. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C; Bouabdallah R; Ysebaert L; Sancho JM; Salles G; Cordoba R; Pinto A; Gharibo M; Rasco D; Panizo C; Lopez-Martin JA; Santoro A; Salar A; Damian S; Martin A; Verhoef G; Van den Neste E; Wang M; Couto S; Carrancio S; Weng A; Wang X; Schmitz F; Wei X; Hege K; Trotter MWB; Risueño A; Buchholz TJ; Hagner PR; Gandhi AK; Pourdehnad M; Ribrag V
Blood; 2020 Mar; 135(13):996-1007. PubMed ID: 31977002
[TBL] [Abstract][Full Text] [Related]
66. Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.
Matsuki E; Bohn OL; El Jamal S; Pichardo JD; Zelenetz AD; Younes A; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):572-580. PubMed ID: 30106758
[TBL] [Abstract][Full Text] [Related]
67. CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma.
Enblad G; Karlsson H; Loskog AS
Hum Gene Ther; 2015 Aug; 26(8):498-505. PubMed ID: 26230974
[TBL] [Abstract][Full Text] [Related]
68. Experimental verification of a conserved intronic microRNA located in the human TrkC gene with a cell type-dependent apoptotic function.
Dokanehiifard S; Soltani BM; Parsi S; Hosseini F; Javan M; Mowla SJ
Cell Mol Life Sci; 2015 Jul; 72(13):2613-25. PubMed ID: 25772499
[TBL] [Abstract][Full Text] [Related]
69. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
[TBL] [Abstract][Full Text] [Related]
70. Coexpression analysis of large cancer datasets provides insight into the cellular phenotypes of the tumour microenvironment.
Doig TN; Hume DA; Theocharidis T; Goodlad JR; Gregory CD; Freeman TC
BMC Genomics; 2013 Jul; 14():469. PubMed ID: 23845084
[TBL] [Abstract][Full Text] [Related]
71. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
Cai QC; Liao H; Lin SX; Xia Y; Wang XX; Gao Y; Lin ZX; Lu JB; Huang HQ
Med Oncol; 2012 Dec; 29(4):2317-22. PubMed ID: 22198695
[TBL] [Abstract][Full Text] [Related]
72. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.
Chng WJ; Gertz MA; Chung TH; Van Wier S; Keats JJ; Baker A; Bergsagel PL; Carpten J; Fonseca R
Leukemia; 2010 Apr; 24(4):833-42. PubMed ID: 20220778
[TBL] [Abstract][Full Text] [Related]
73. Accounting for one-channel depletion improves missing value imputation in 2-dye microarray data.
Ritz C; Edén P
BMC Genomics; 2008 Jan; 9():25. PubMed ID: 18205949
[TBL] [Abstract][Full Text] [Related]
74. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
75. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
76. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
77. National Oncology Forum: perspectives for the year 2000.
DeVita VT; Bleickardt EW
Cancer J; 2001; 7 Suppl 1():S2-13. PubMed ID: 11504281
[TBL] [Abstract][Full Text] [Related]
78. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
Cillessen SA; Meijer CJ; Notoya M; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2010 Apr; 220(5):509-20. PubMed ID: 20087881
[TBL] [Abstract][Full Text] [Related]
79. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
Linderoth J; Edén P; Ehinger M; Valcich J; Jerkeman M; Bendahl PO; Berglund M; Enblad G; Erlanson M; Roos G; Cavallin-Ståhl E
Br J Haematol; 2008 May; 141(4):423-32. PubMed ID: 18419622
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
